Poly Medicure Ltd Q4 FY25 Earnings Analysis

- Poly Medicure aims for a sustained growth rate of 20%+ annually, seen consistently over the past 3-4 years. - Infusion therapy (70% revenue) and renal products (8-9% revenue) to drive growth with renal showing 56% growth recently. - Domestic business targeting over 20% growth, improving from a low start. - Exports grew around 28-30%; emphasis on US and Europe with expected regulatory approvals driving future gains. - Dialysis business expanding with standalone and daycare centers boosting demand; target 20-25% market share in renal by 2030. - Planned CAPEX of Rs. 400-500 crores over 18-20 months for new plants to support capacity expansion. - Addition of 50 new product SKUs in 1-2 years across cardiology, critical care, vascular, and renal categories. - Continuous sales team expansion, with 100 new hires planned yearly for next 3-4 years to deepen market penetration.

- Poly Medicure targets a sustained revenue growth of around 20%+ annually over the next 3-5 years, building on the recent 20%-plus growth trajectory. - EBITDA margins are expected to improve by approximately 50-100 basis points per year, driven by operational efficiencies and scale benefits. - Introduction of higher-margin businesses like oncology and critical care is anticipated to contribute positively to margin expansion. - The company has recently added 60+ sales and marketing personnel in new verticals, expecting ramp-up over 2-3 years to enhance revenue. - CAPEX cycle includes ongoing and planned investments (~Rs. 400-500 crores) in new plants to support future growth. - Profitability (PAT) growth is expected to align with revenue and margin improvements, supported by steady operational leverage. - Overall, future profits/EPS growth appear sustainable and predictable, with a healthy outlook backed by product innovation, capacity expansion, and domestic/international market growth.

- Current CAPEX: Rs. 222 crores invested in 9 months FY25; plan for Rs. 300 crores total this year. - This CAPEX primarily for existing plants, funded through internal accruals, not QIP proceeds. - Future CAPEX: Rs. 400-500 crores planned over next 18-20 months for three new plants under construction in Palwal, Haryana. - These new plants expected to be commissioned by mid-2026. - All QIP proceeds (Rs. 500 crores) will be utilized for new CAPEX related to these new plants. - Strategic investments include a JV with AMPIN for 9.9 MW solar power to run manufacturing on green energy by late 2024/early 2025. - Focus on launching ~50 new product SKUs over 1-2 years, including oncology, critical care, vascular, and renal categories. - Exploration of potential acquisition targets in critical care, oncology, or cardiology sectors, with announcements pending if any materialize.

- The company has completed a QIP (Qualified Institutional Placement) and the proceeds are being designated primarily for new CAPEX and acquisitions. - Rs. 500 crores of QIP proceeds are earmarked for new CAPEX, specifically for building three new plants expected to be ready in 18 to 20 months. - Current CAPEX of around Rs. 222 crores done over 9 months this year was funded through internal accruals, not QIP. - No specific mention of any new future fundraising plans through debt or further equity beyond the QIP at this stage. - The company is open to announcing acquisitions if targets are identified, potentially funded from QIP proceeds. Summary: Poly Medicure is utilizing existing QIP funds for expansion with no stated immediate plans for additional debt or equity fundraising.

The transcript does not provide specific details regarding the current or expected order book or pending orders for Poly Medicure Limited. However, the following related information is available: - The company is actively expanding with new plants under construction, expected to be operational in 18 to 20 months. - Focus is on expanding domestic market presence by hiring more sales and marketing staff, aiming to increase wallet share in more hospitals. - The company expects export growth of over 20% in key geographies like the US and Europe. - New product launches (about 50 products within 1-2 years) and entry into new verticals such as oncology and critical care are expected to drive future order flow. - Dialysis equipment business is growing with a run rate of 40-50 machines sold per month. - No explicit mention or figures related to order book or pending orders were disclosed in the provided transcript.